NCT03248531 - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 22, 2017

Primary Completion Date

November 23, 2018

Study Completion Date

February 21, 2019

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

Bimekizumab

Bimekizumab in different dosages (dose 1 and 2).

DRUG

Adalimumab

Adalimumab in different dosages (dose 1, 2 and 3).

OTHER

Placebo

Placebo will be provided matching Bimekizumab.

Trial Locations (31)

11030

Hs0001 126, Manhasset

17033

Hs0001 123, Hershey

27599

Hs0001 125, Chapel Hill

30328

Hs0001 112, Sandy Springs

32073

Hs0001 111, Orange

33134

Hs0001 119, Coral Gables

33624

Hs0001 117, Tampa

37215

Hs0001 120, Nashville

89074

Hs0001 115, Las Vegas

90033

Hs0001 121, Los Angeles

02215

Hs0001 113, Boston

Unknown

Hs0001 103, East Melbourne

Hs0001 101, Fremantle

Hs0001 104, Saint Leonards

Hs0001 100, Westmead

Hs0001 102, Woolloongabba

Hs0001 203, Brussels

Hs0001 202, Liège

Hs0001 300, Copenhagen

Hs0001 408, Berlin

Hs0001 405, Bochum

Hs0001 407, Darmstadt

Hs0001 400, Dessau

Hs0001 404, Erlangen

Hs0001 406, Würzburg

Hs0001 503, Athens

Hs0001 701, Harstad

Hs0001 700, Tromsø

Hs0001 901, Moscow

Hs0001 903, Saint Petersburg

Hs0001 900, Yaroslavl

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY